Contineum Therapeutics, Inc. (CTNM)
17.04
0.00 (0.00%)
USD |
NASDAQ |
Aug 26, 16:00
17.04
0.00 (0.00%)
After-Hours: 17:24
Contineum Therapeutics Debt to Equity Ratio : 0.0274 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0274 |
| March 31, 2026 | 0.0278 |
| December 31, 2025 | 0.0316 |
| September 30, 2025 | 0.0304 |
| June 30, 2025 | 0.0335 |
| March 31, 2025 | 0.0325 |
| December 31, 2024 | 0.0316 |
| September 30, 2024 | 0.0029 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0027 |
| March 31, 2024 | -2.555 |
| December 31, 2023 | -2.844 |
| September 30, 2023 | -3.169 |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -1.484 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 1.284 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0146 |
| Fulcrum Therapeutics, Inc. | 0.017 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 250.37M |
| Total Liabilities (Quarterly) | 10.71M |
| Shareholders Equity (Quarterly) | 239.66M |
| Current Ratio | 37.17 |
| Net Debt Paydown Yield | -0.02% |